S-1a monotherapy for pancreatic cancer

When treating pancreatic cancer, various drugs are often indispensable, among which S-1 is a typical one. So, how effective is S-1 in treating pancreatic cancer? How to care for pancreatic cancer patients after surgery? As a new oral fluorouracil combination preparation, S-1 was first successfully used in gastric cancer patients in Japan. With the development of clinical research, the indications have gradually expanded. It has been successfully used in the treatment of various solid tumors, including the treatment of metastatic pancreatic cancer.

Pancreatic cancer is a highly malignant digestive tract tumor with a high degree of malignancy and a poor prognosis. The current drug treatments mainly include gemcitabine, fluorouracil and its oral preparations, FOLFOXIRI regimen and erlotinib, etc., all of which have low efficacy. Due to the obvious adverse reactions caused by combined chemotherapy, the quality of life score and age of patients are required to be high, and the elderly and weak are mostly unable to tolerate it. The molecular targeted drug erlotinib is expensive and must be paid for by the patient. At the same time, clinical trials show that the PFS benefit of patients is only two weeks, so its clinical use is also limited.
Studies have confirmed that capecitabine can effectively treat pancreatic cancer, and S-100 should be more valuable as a combination preparation. Considering that most patients with advanced pancreatic cancer are elderly and have low quality of life scores, we chose to conduct a clinical study on the treatment of advanced pancreatic cancer with S-100 monotherapy.